On May 8, on the eve of the Mevos International Congress of Aesthetic Surgery and Medicine, the Innovative Biomaterials Aesthetic Medicine Solutions Seminar and BloomseaN New Product Launch was grandly held in Hangzhou. Industry experts and partners from across the country gathered to witness a feast of ideas focused on biomaterial innovation and the future of aesthetic medicine.
Industry Leaders Gather, Insights Abound
The seminar began with an inspiring opening speech by Mr. Zou Songyan, Vice President of Business Operations of Bloomage. Mr. Zou emphasized the company’s comprehensive upgrade across business processes, organizational talent, and digital intelligence through three key strategies: strategic transformation, innovation focus, and building a strategic ecosystem. Driven by synthetic biology and focused on glycobiology and cell biology, Bloomage aims to leverage its full-chain industry transformation capabilities to provide integrated “raw materials + technology + applications” services and accelerate global expansion. Bloomage is actively building an open strategic ecosystem, empowering aesthetic medicine clients through innovative products and shaping the future of the industry together.
Mr. Shen Shiyuan, General Manager of Bloomage’s Pharmaceutical Materials Division, provided a global perspective on the current state of the aesthetic medicine market. He offered an in-depth introduction to the company’s development history and strategic layout, including the market share and distribution of medical aesthetic injectable-grade HA, highlighting Bloomage’s deep expertise and innovation in the field of biomaterials for aesthetics.
New Product Launch
The highlight of the seminar was the official launch of BloomseaN™! As a synthetic biology-driven biotech company with a full-industry-chain platform in biomaterials, Bloomage focuses on glycobiology and cell biology. From upstream R&D to raw material production and brand building, the company explores a full-chain biomaterial transformation path. Leveraging its industrial transformation advantage in synthetic biology, Bloomage provides scientific solutions for life and health.
Based on a product development logic that uses glycobiology to inspire cell biology—achieving regenerative effects through cell regulation—R&D Director Wang Rui delivered an in-depth presentation on the scientific breakthrough of PDRN. Derived from marine organisms, its active ingredients help reconstruct a healthy ECM (extracellular matrix), efficiently promote the production of collagen, elastin, and hyaluronic acid, maintain ECM homeostasis, repair ECM structure, reduce ECM degradation, and ultimately achieve physiological tissue regeneration.
Industry Trend Analysis
Mr. Xiaodong, founder of JMOLY, shared insights on “Current Status and Trends in the Medical Aesthetics Market,” offering a deep analysis of user demographics, material trends, and how to identify a “second growth curve,” providing attendees with a forward-looking view of the industry.
Technology Empowering Aesthetic Medicine
Bloomage’s senior expert in pharmaceutical and device packaging, Ms. Qi Xiaoling, and senior product manager in pharmaceutical materials, Ms. Li Meiyan, presented on the topics of “Compatibility Studies on Packaging Materials for Aesthetic Injectables” and “Innovative Solutions in Active Polymer Aesthetic Medicine.” Their presentations explored the scientific mechanisms and innovative applications of biomaterials, showcasing the Bloomage’s leading edge in R&D.
Clinical Practice Sharing
Dr. Wang Yan, Director of Face+ aesthetic clinic in Hangzhou, presented on “Comprehensive Injection Aesthetic Treatment Plans.” From a clinical perspective, she analyzed the practical applications and efficacy optimization of biomaterials in aesthetic injections, offering valuable hands-on experience to the audience.
Regulatory and Policy Interpretation
Mr. Dongfang Wang, Senior Manager of Regulatory Affairs and Registration at Bloomage, provided a policy-based analysis of “Key Points in the Development and Regulatory Review of Injectable Aesthetic Products.” By tracing the development path of the aesthetic medicine industry and explaining Bloomage’s development logic for medical aesthetic products, she offered an in-depth look at the essentials for developing and registering injectable products, helping streamline the registration of end formulations.
This seminar was not only a profound exchange of industry knowledge, but also a new beginning for collaboration between Bloomage and its partners. Moving forward, the company will continue to be innovation-driven and customer-oriented, providing high-quality biomaterial solutions for the aesthetic medicine industry!
